What the heart trial actually showed.

For its first few years in wide use, the GLP-1 was understood as a weight-loss drug that happened to have started as a diabetes drug. Then a trial called SELECT read out, and the understanding shifted. SELECT enrolled more than seventeen thousand adults who had established cardiovascular disease and obesity but who did not have diabetes. It asked a single question. In people like this, does semaglutide prevent heart attacks and strokes. The answer was yes.

Here is the result that mattered.

What the numbers mean

Over a follow-up of roughly three years, eight percent of the patients on placebo had a major cardiovascular event, defined as cardiovascular death, a non-fatal heart attack, or a non-fatal stroke. Among the patients on semaglutide, that figure was six and a half percent.¹ The relative reduction was twenty percent. The hazard ratio, the number cardiologists actually quote, was 0.80.

Twenty percent is a large effect for a cardiovascular drug. It is in the same range as some statins and blood-pressure medications, the drugs that form the backbone of heart-attack prevention. What made the SELECT result land so hard was not the size of the effect. It was who it happened in.

Why the absence of diabetes mattered

Before SELECT, the cardiovascular benefits of GLP-1s had been shown mainly in people with type 2 diabetes, where it was reasonable to assume the benefit ran partly through better blood-sugar control. SELECT removed that explanation. None of these patients had diabetes. Whatever was protecting their hearts, it was not glucose management.²

That pointed to something more fundamental. The drug appeared to be acting on the cardiovascular system directly, through some combination of weight loss, reduced inflammation, improved blood pressure, and effects on the blood vessels themselves that researchers are still mapping. The benefit began to separate from placebo early, before most of the weight loss had happened, which suggests that weight loss alone does not explain all of it.³

None of these patients had diabetes. Whatever was protecting their hearts, it was not blood-sugar control.

Is it the weight or the drug

This is the open question, and it matters more than it sounds. If the cardiovascular benefit comes entirely from weight loss, then any effective weight-loss method should produce it. If the benefit comes partly from the drug acting directly on the cardiovascular system, then the drug is doing something a diet cannot. The early-separation pattern, and the fact that the benefit did not track neatly with how much weight each patient lost, points toward the second explanation, at least in part.³

The honest answer is that it is probably both, in proportions that are not yet settled. The trial was not designed to separate the two cleanly, and the analyses that have tried to are suggestive rather than definitive.

What changed because of it

SELECT changed the regulatory and clinical status of semaglutide. On the strength of the trial, the drug was approved specifically to reduce cardiovascular risk in adults with cardiovascular disease and obesity, separate from any diabetes or weight indication.⁴ That distinction is not academic. It changed who insurers were willing to cover, because a drug that prevents heart attacks is a different proposition to a payer than a drug that reduces weight.

It also reframed the entire category. A GLP-1 is no longer best understood as a weight-loss drug with cardiovascular side benefits. For a large group of patients, it is a cardiovascular drug whose mechanism happens to include weight loss. For a woman over fifty weighing the decision, that reframing is the most important thing SELECT produced.

Editorial content. Not medical advice. The findings above come from the published SELECT trial and its secondary analyses; individual response varies and the trial studied a specific high-risk population. Talk to your prescriber or cardiologist before starting or changing any medication.